OSE Immunotherapeutics SA announced that the Independent Data Monitoring Committee for the company’s international pivotal Phase 3 clinical study (Atalante 1) of Tedopi for the treatment of non-small cell lung cancer has unanimously recommended continuation of the trial, without asking for modifications. As specified in the study protocol of Atalante 1, the IDMC meets on a regular basis to review data from the ongoing trial. The IDMC is a group of independent experts, external to the study, who assess the progress, safety data and critical efficacy endpoints of the clinical trial for safeguarding the interest of study participants. Based on its review, the IDMC provides the sponsor and the Steering committee with recommendations regarding study modification, continuation or termination. IDMCs are customary for large, randomized, multi-site studies, such as Atalante 1. The international Atalante 1 pivotal Phase 3 study is designed to evaluate the benefits of Tedopi compared to current standard chemotherapies (docetaxel or premetrexed, both approved as 2nd line treatments) in HLA-A2 positive patients with stage IIIB (locally advanced) or IV (metastatic) NSCLC who have failed platinium-based therapy or 2nd line checkpoint inhibitor therapy. As recent clinical evidence has demonstrated positive results with checkpoint inhibitors in 1st line therapy, the study population has been extended to patients who received checkpoint inhibitors either as 1st or 2nd line therapy. This registration trial will include 500 patients and results are expected to be reported in late 2018.